Prevalence of @entity5892 in @entity1 with XXXX .

@entity1 @entity6582 @entity64 @entity5892 @entity854 @entity299 @entity715 @entity385
BACKGROUND: @entity1 with @entity299 ( @entity299 ) have a high prevalence of @entity715 , the most frequently described locations being the cerebral and pulmonary vessels. The reported prevalence of both @entity385 and @entity715 has been highly variable. The aim of this study was to examine the prevalence of both @entity5892 in @entity299 according to medical history and imaging. In addition, the role of known @entity6582 and @entity854 as risk factors was evaluated. METHODS AND RESULTS: A cross-sectional descriptive study examining 98 stable adult @entity1 with @entity299 with a medical questionnaire, blood samples, MRI of the cerebrum (n=72), multidetector CT imaging (MDCT) of the thorax (n=76) and pulmonary scintigraphy (ventilation/perfusion/single-photon emission computerised tomography/CT) (n=66). The prevalence of @entity385 and @entity715 according to imaging were 47% and 31%, respectively. Comparing the findings with previous medical history revealed a large under-reporting of @entity715 with only 22% of the @entity1 having a clinical history of @entity64 and 25% of @entity715 . There was no association between the degree of @entity6582 or @entity854 and the prevalence of @entity715 . CONCLUSIONS: @entity1 with @entity299 have a prevalence of both @entity5892 of around 30%-40%, which is much higher than that reported previously. Furthermore, there is a large discrepancy between clinical history and imaging findings, suggesting a high prevalence of silent @entity715 events. Neither @entity6582 nor @entity854 were associated with the prevalence of @entity715 in @entity1 with @entity299 . TRIAL REGISTRATION NUMBER: http://www.cvk.sum.dk/CVK/Home/English.aspx (H-KF-2006-4068).
